Literature DB >> 15976181

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

Matthias Gunzer1, Helge Riemann, Yasmin Basoglu, Anja Hillmer, Carsten Weishaupt, Sandra Balkow, Bernd Benninghoff, Beat Ernst, Meike Steinert, Thomas Scholzen, Cord Sunderkötter, Stephan Grabbe.   

Abstract

Toll-like receptor (TLR) ligands lead to the induction of proinflammatory cytokines and are potent enhancers of specific immune responses. We show here that a single systemic dose of R-848, a ligand for TLR7, potently enhanced hapten sensitization during the induction of contact hypersensitivity (CHS). However, R-848 administration also resulted in a rapid and almost complete depletion of leukocytes from the blood. This effect was transient and was associated with general induction of endothelial adhesiveness. In response to R-848, endothelial cells up-regulated adhesion molecules in vitro and in vivo and leukocytes exhibited increased rolling on endothelia in R-848-treated animals. Adhesion molecule induction appeared to be a direct effect, because endothelial cells expressed TLR7 in vitro and in vivo. After R-848 treatment, the tissue residence time of leukocytes was markedly prolonged in all major peripheral organs. The resulting transiently reduced availability of peripheral-blood leukocytes (PBLs) (TRAP) significantly inhibited otherwise potent CHS responses until the effector cells returned. Thus, although TLR7 ligands are effective adjuvants for the induction of cell-mediated immunity, they can transiently inhibit the elicitation of localized immune responses, possibly due to a systemic endothelial activation throughout the vasculature.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976181     DOI: 10.1182/blood-2005-01-0342

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  TLR-7 Stress Signaling in Differentiating and Mature Eosinophils Is Mediated by the Prolyl Isomerase Pin1.

Authors:  Zhong-Jian Shen; Jie Hu; Venkatesh Kashi; Yury A Bochkov; James E Gern; James S Malter
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

2.  Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.

Authors:  Jonathan P Butchar; Payal Mehta; Steven E Justiniano; Kristan D Guenterberg; Sri-Vidya Kondadasula; Xiaokui Mo; Mahesh Chemudupati; Thirumala-Devi Kanneganti; Amal Amer; Natarajan Muthusamy; David Jarjoura; Clay B Marsh; William E Carson; John C Byrd; Susheela Tridandapani
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

Review 3.  Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?

Authors:  Jan Heidemann; Wolfram Domschke; Torsten Kucharzik; Christian Maaser
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke.

Authors:  Frances Rena Bahjat; Rebecca L Williams-Karnesky; Steven G Kohama; G Alexander West; Kristian P Doyle; Maxwell D Spector; Theodore R Hobbs; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2011-02-02       Impact factor: 6.200

Review 5.  Beyond empiricism: informing vaccine development through innate immunity research.

Authors:  Stuart M Levitz; Douglas T Golenbock
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

6.  Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.

Authors:  Hannah Perkins; Tansi Khodai; Houria Mechiche; Peter Colman; Frances Burden; Carl Laxton; Nigel Horscroft; Tom Corey; Deborah Rodrigues; Jaiessh Rawal; Jonathan Heyen; Mark Fidock; Mike Westby; Helen Bright
Journal:  J Clin Immunol       Date:  2012-04-05       Impact factor: 8.317

7.  Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.

Authors:  Jing Wang; Yuko Shirota; Defne Bayik; Hidekazu Shirota; Debra Tross; James L Gulley; Lauren V Wood; Jay A Berzofsky; Dennis M Klinman
Journal:  J Immunol       Date:  2015-03-30       Impact factor: 5.422

8.  Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.

Authors:  Hélène G Bazin; Laura S Bess; Mark T Livesay; Yufeng Li; Van Cybulski; Shannon M Miller; David A Johnson; Jay T Evans
Journal:  Bioorg Med Chem Lett       Date:  2020-01-22       Impact factor: 2.823

9.  CCN1/CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation.

Authors:  Beat A Imhof; Stephane Jemelin; Romain Ballet; Christian Vesin; Marc Schapira; Melis Karaca; Yalin Emre
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

10.  The immunorecognition, subcellular compartmentalization, and physicochemical properties of nucleic acid nanoparticles can be controlled by composition modification.

Authors:  Morgan Brittany Johnson; Justin R Halman; Daniel K Miller; Joseph S Cooper; Emil F Khisamutdinov; Ian Marriott; Kirill A Afonin
Journal:  Nucleic Acids Res       Date:  2020-11-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.